Zomedica Corp (AMEX: ZOM)’s stock price has soared by 3.77 in relation to previous closing price of 0.17. Nevertheless, the company has seen a loss of -3.67% in its stock price over the last five trading days. Accesswire reported 2023-11-20 that ANN ARBOR, MI / ACCESSWIRE / November 20, 2023 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that the management team will attend the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28, 2023. Zomedica CEO Larry Heaton will be presenting a Company overview and business outlook at 10:30 a.m.

Is It Worth Investing in Zomedica Corp (AMEX: ZOM) Right Now?

compared to its average ratio and a 36-month beta value of 0.95. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


The average price point forecasted by analysts for Zomedica Corp (ZOM) is $0.44, which is $0.27 above the current market price. The public float for ZOM is 964.81M, and currently, short sellers hold a 6.52% ratio of that float. The average trading volume of ZOM on November 20, 2023 was 3.42M shares.

ZOM’s Market Performance

ZOM stock saw an increase of -3.67% in the past week, with a monthly gain of 4.77% and a quarterly increase of -3.83%. The volatility ratio for the week is 5.89%, and the volatility levels for the last 30 days are 6.24% for Zomedica Corp (ZOM). The simple moving average for the past 20 days is 1.27% for ZOM’s stock, with a -14.24% simple moving average for the past 200 days.

Analysts’ Opinion of ZOM

Many brokerage firms have already submitted their reports for ZOM stocks, with Dawson James repeating the rating for ZOM by listing it as a “Buy.” The predicted price for ZOM in the upcoming period, according to Dawson James is $6 based on the research report published on January 06, 2023 of the current year 2023.

ZOM Trading at 1.86% from the 50-Day Moving Average

After a stumble in the market that brought ZOM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.24% of loss for the given period.

Volatility was left at 6.24%, however, over the last 30 days, the volatility rate increased by 5.89%, as shares surge +3.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.40% lower at present.

During the last 5 trading sessions, ZOM fell by -4.67%, which changed the moving average for the period of 200-days by -38.80% in comparison to the 20-day moving average, which settled at $0.1715. In addition, Zomedica Corp saw 6.38% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ZOM starting from HEATON LARRY C II, who purchase 100,000 shares at the price of $0.17 back on Nov 17. After this action, HEATON LARRY C II now owns 200,000 shares of Zomedica Corp, valued at $16,600 using the latest closing price.

POWERS JOHNNY D, the Director of Zomedica Corp, purchase 150,000 shares at $0.17 during a trade that took place back on Nov 15, which means that POWERS JOHNNY D is holding 1,750,000 shares at $25,950 based on the most recent closing price.

Stock Fundamentals for ZOM

Current profitability levels for the company are sitting at:

The net margin for Zomedica Corp stands at -89.88. The total capital return value is set at -8.10, while invested capital returns managed to touch -6.30. Equity return is now at value -5.64, with -5.36 for asset returns.

Based on Zomedica Corp (ZOM), the company’s capital structure generated 0.65 points at debt to equity in total, while total debt to capital is 0.65. Total debt to assets is 0.62, with long-term debt to equity ratio resting at 0.41. Finally, the long-term debt to capital ratio is 0.41.

When we switch over and look at the enterprise to sales, we see a ratio of 2.10, with the company’s debt to enterprise value settled at 0.04. The receivables turnover for the company is 14.40 and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.81.


To put it simply, Zomedica Corp (ZOM) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.